Showing results (271-280 of 369) with videos related to
Sort By:
Pageof 37
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2005
The progress and promise of molecular imaging probes in oncologic drug developmentGary J Kelloff, Kenneth A Krohn, Steven M Larson, et al.Urology|November 27, 2016
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate CancerMatthew J O'Shaughnessy, Sean M McBride, Hebert Alberto Vargas, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 13, 2016
First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion UptakeNeeta Pandit-Taskar, Joseph A O'Donoghue, Shutian Ruan, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2015
Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 resultsMichael J Morris, Arturo Molina, Eric J Small, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancerDana Rathkopf, Glenn Liu, Michael A Carducci, et al.Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.Nature Communications|April 26, 2018
Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancerMichael R McDevitt, Daniel L J Thorek, Takeshi Hashimoto, et al.Pageof 37